Key result
Lp(a) screening may improve cardiovascular risk stratification as an independent risk factor.
Answers are grounded in this paper and cite their sources.
Lipoprotein(a) is an independent cardiovascular risk factor, and its integration into routine screening may help identify individuals at elevated risk to tailor preventive interventions.
Lipoprotein(a) (Lp(a)) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), independent of traditional risk factors such as low-density lipoprotein cholesterol (LDL-C). Major societies now broadly recognize Lp(a) as an independent cardiovascular risk factor, recommending universal screening among adults or at least targeted screening among select higher-risk groups. This article synthesizes current knowledge of the biochemistry, pathophysiology, clinical significance, laboratory assessment, available management options, and emerging therapies for elevated Lp(a) levels. Many guidelines suggest that Lp(a) testing is ready for broader clinical implementation, and its integration into routine practice may assist health care providers in identifying individuals at elevated cardiovascular risk and tailoring preventive interventions accordingly.
No takes yet. Share an insight, caveat, or question.
Nolan Crain (2026) conducted a review in Atherosclerotic cardiovascular disease. Lipoprotein(a) screening was evaluated. Lipoprotein(a) is an independent cardiovascular risk factor, and its integration into routine practice through universal or targeted screening may assist in identifying individuals at elevated risk.
Synapse has enriched 10 related papers. Consider them for comparative context: